Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gerdoff
- Development stage
- Unknown
- Lead developer
- SOFAR
- Administration
- Oral
01
Overview
Gerdoff is a Class 3 CE-marked medical device developed by SOFAR S.p.A. for the symptomatic treatment of gastroesophageal reflux disease (GERD). It is a fixed-dose combination of hyaluronic acid, chondroitin sulfate, and aluminum hydroxide, formulated as orodispersible tablets. The product exerts its effect through a mechanical barrier mechanism, adhering to the esophageal mucosa to provide protection against gastric fluids while stimulating salivation and mucus secretion. It is used to alleviate symptoms such as heartburn, acid regurgitation, and epigastric pain, particularly in patients refractory to alginate therapy or as an adjunct to proton pump inhibitors (PPIs).
- Brand names
- GerdoffGerdoff Protection
- Other names
- GERDOFF®
Beyond the preview
Go deeper on Gerdoff.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gerdoff.